Curium to Acquire Lantheus in Up to $8 Billion Radiopharmaceutical Deal

Curium US Holdings LLC has agreed to acquire Lantheus Holdings Inc. in a transaction with a maximum value of approximately $8 billion. Lantheus shareholders will receive $102.50 per share in cash at closing, plus contingent value rights (CVRs) of up to $12 per share tied to commercial milestones. Lantheus will merge with a wholly owned subsidiary of Curium and will lose its public company status upon closing. The transaction is expected to close in the first half of 2027 and is not subject to a financing condition.

The CVR payments are linked to Lantheus's specific prostate cancer, neurology, and other product lines reaching defined sales targets through 2030. This structure allocates pipeline risk between buyer and seller: Curium pays the base price for Lantheus's existing business, while sellers retain upside participation if key products outperform. CVR agreements of this type require careful drafting of sales calculation methodologies, anti-bundling provisions, distribution strategy constraints, and the standard of commercial effort the acquirer must apply to achieve the milestones.

The combined company will control a significant portion of the radiopharmaceutical value chain — from radioisotope production and global manufacturing infrastructure through to diagnostic products and therapies. This vertical integration is operationally significant given the short shelf life of radioactive isotopes and the specialized distribution requirements of nuclear medicine products. Curium, already a major global radiopharmaceutical manufacturer, gains Lantheus's commercial infrastructure and late-stage pipeline in oncology and neurology imaging.

Lantheus is a leading developer and manufacturer of diagnostic imaging agents and radiopharmaceutical therapeutics. Its portfolio includes products used in cardiac imaging, prostate cancer detection, and neurological assessment. The company has been a beneficiary of growing clinical adoption of radiopharmaceutical therapies, particularly in oncology, where targeted radiotherapy is gaining ground as a treatment modality.

The transaction involves a particularly complex regulatory landscape. In addition to standard antitrust and merger control filings in the United States and potentially other jurisdictions, the deal requires review of radioactive material licenses, nuclear facility permits, transportation authorizations, and occupational safety approvals on a facility-by-facility basis.

Isotope production capacity, sole-source supply arrangements, hospital distribution networks, and reimbursement pricing are distinct risk areas that require thorough due diligence. The CVR agreement demands precise drafting: how sales are calculated, whether products can be bundled with other brands, how distribution strategy changes affect milestone achievement, and what standard of commercial effort Curium must demonstrate are all points that will be heavily negotiated and litigated if milestones are missed.

The Curium–Lantheus deal, alongside the KKR–Integer transaction announced in the same period, reflects sustained private equity and strategic interest in healthcare infrastructure assets. Radiopharmaceuticals in particular have attracted significant capital as the clinical and commercial case for targeted radiotherapy in oncology has strengthened over the past several years.

ULF New York Consulting Inc. advises Turkish companies on U.S. market entry, cross-border M&A, and regulatory compliance. This analysis is provided for informational purposes only and does not constitute legal advice.